Published in Hepatitis Weekly, February 13th, 2006
"The susceptibility of adefovir-resistant HBV mutants is only reduced by 3-10-fold in in vitro studies, suggesting that virologic breakthrough and clinical deterioration are unlikely. The aim of this study was to describe the clinical course of patients with adefovir-resistant HBV infection," wrote S.K. Fung and colleagues, University of Michigan.
"Testing for adefovir-resistant mutations was performed on patients who had a suboptimal response or virologic breakthrough on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.